About Micreos

Micreos, located in Zug Switzerland, is a Dermatology focused biotech company with a long-standing, collaboration with the pre-eminent University, ETH, Zurich.

Our superior, engineered endolysin technology quickly eliminates harmful pathogens that aggravate and amply disease progression across multiple medical indications.

Our ‘lead’ medical indication is Atopic Dermatitis, a highly prevalent medical condition with a huge unmet medical need and a global prevalence of 20% in children and 3% in adults. Patients with Atopic Dermatitis have a disturbed skin barrier function as a genetic predisposition. The harmful pathogen Staphylococcus aureus (S. aureus) then actively colonises and overgrows on this compromised skin, worsening the skins barrier dysfunction and increasing vulnerability and permeability. S. aureus produces toxins, proteases, and superantigens that punch holes in the skin’s defences triggering an immune response and triggering flare initiation.
S. aureus superantigens are also potent immunomodulators that activate the immune system and sustain chronic inflammation in these AD patients. S. aureus proteases such as V8 also directly activate neuronal PAR-1 triggering itch and reinforcing the itch–scratch cycle.
Our therapeutic focus in Micreos is to quickly, effectively and safely eliminate the harmful pathogen that causes disease aggravation and progression and restore the skins natural microbiome in Dermatological conditions.

MEndoB – our ‘lead’ molecule – is a highly effective ‘dual acting molecular domain’ Engineered Endolysin that effectively eliminates Staphylococcus aureus (S. aureus) – the triggering pathogen present in up to 90% of Atopic Dermatitis patients.
Pre-clinical data for MEndoB confirms 1) Safety (which is a critical characteristic especially for vulnerable populations like young children where the prevalence is so high and current treatment standards-of-care are suboptimal), 2) High efficacy (also against hard to clear biofilms), 3) No known drug resistance (that is critical for chronic therapies), 4) Specificity against S. aureus (with no off-target effects), and 5) Broad activity profile on the skin (including at the low pH of diseased AD skin).
Our ultimate Vision is that MEndoB will be a foundational therapy option for patients living with Atopic Dermatitis. We intend to enter clinical trials with MEndoB in AD patients in late 2026.